We are live on
!
Find out more
SGH
Sivik Global Healthcare Portfolio holdings
AUM
$132M
1-Year Est. Return
24.1%
This Fund
S&P 500
This Quarter
Est. Return
+2.91%
1 Year Est. Return
+24.1%
3 Year Est. Return
+53.78%
5 Year Est. Return
+97.1%
10 Year Est. Return
+690.63%
AUM
$368M
AUM Growth
+$183M
(+99%)
Cap. Flow
+$177M
Cap. Flow
% of AUM
48.23%
Top 10 Holdings %
Top 10 Hldgs %
48.89%
Holding
49
New
18
Increased
17
Reduced
7
Closed
3
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Quest Diagnostics
DGX
|
+$4.34M |
| 2 |
Bio-Rad Laboratories Class A
BIO
|
+$4.26M |
| 3 |
Revvity
RVTY
|
+$4.24M |
| 4 |
UnitedHealth
UNH
|
+$3.82M |
| 5 |
Repligen
RGEN
|
+$3.82M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$5.14M |
| 2 |
Encompass Health
EHC
|
+$3.04M |
| 3 |
Baxter International
BAX
|
+$3.03M |
| 4 |
Boston Scientific
BSX
|
+$2.02M |
| 5 |
Abbott
ABT
|
+$765K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 55.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Smith & Nephew
SNN
$12.6B
| $4.29M | 1.17% |
140,000
+20,000
| +17% | +$564K |
|
|
27
Repligen
RGEN
$9.45B
| $3.73M | 1.02% |
+30,000
| New | +$3.82M |
|
28
West Pharmaceutical
WST
$24.4B
| $3.28M | 0.89% |
15,000
+2,500
| +20% | +$534K |
|
|
29
Encompass Health
EHC
$12.2B
| $3.07M | 0.83% |
25,000
-26,600
| -52% | -$3.04M |
|
30
Avantor
AVTR
$9.37B
| $3.03M | 0.82% |
225,000
+25,000
| +13% | +$342K |
|
31
Align Technology
ALGN
$12.5B
| $2.84M | 0.77% |
+15,000
| New | +$2.65M |
|
32
Surgery Partners
SGRY
$1.99B
| $2.78M | 0.76% |
125,000
| – | – |
|
|
33
Baxter International
BAX
$14B
| $2.27M | 0.62% |
75,000
-100,000
| -57% | -$3.03M |
|
34
Cooper Companies
COO
$14.9B
| $2.13M | 0.58% |
+30,000
| New | +$2.3M |
|
35
Alnylam Pharmaceuticals
ALNY
$30.4B
| $2.12M | 0.58% |
+6,500
| New | +$1.8M |
|
36
Madrigal Pharmaceuticals
MDGL
$11.7B
| $1.51M | 0.41% |
+5,000
| New | +$1.49M |
|
37
argenx
ARGX
$53.6B
| $1.38M | 0.37% |
+2,500
| New | +$1.45M |
|
38
Inspire Medical Systems
INSP
$1.68B
| $1.3M | 0.35% |
+10,000
| New | +$1.45M |
|
|
39
AstraZeneca
AZN
$244B
| – | – |
-35,000
| Closed | -$5.14M |
|
40
PUT
Sarepta Therapeutics
SRPT
$1.95B
| – | – |
-20,000
| Closed | -$1.28M |
|
Similar funds
AFP
PCGDR
9C
STFP
AC
EIM
WM
SWM
Sivik Global Healthcare's Q2 2025 Portfolio in Review
As of Q2 2025, Sivik Global Healthcare held 49 positions worth $368M, up 99% from $185M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Sivik Global Healthcare deployed $177M of net new capital in Q2 2025, opening 18 new positions and adding to 17 existing holdings. Its largest new stake was Quest Diagnostics: 25,000 shares worth $4.49M.
By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 88% a quarter earlier.
On the sell side, the largest reduction was Encompass Health, an estimated $3.04M trimmed.
- Sivik Global Healthcare's largest Q2 2025 buy was Quest Diagnostics: 25,000 shares worth $4.49M.
- Sivik Global Healthcare added most to UnitedHealth in Q2 2025, an estimated $3.82M increase.
- Sivik Global Healthcare's biggest Q2 2025 reduction was Encompass Health, cutting an estimated $3.04M.
- Sivik Global Healthcare fully exited AstraZeneca in Q2 2025, selling an estimated $5.14M.
- Sivik Global Healthcare's ten largest holdings make up 49% of its $368M portfolio in Q2 2025.
- Sivik Global Healthcare opened 18 new positions and closed 3 in Q2 2025.
- Sivik Global Healthcare's portfolio value rose 99% quarter-over-quarter to $368M.
Based on Sivik Global Healthcare's 13F filing for Q2 2025, filed 25 Jul 2025.